Gerrit Dispersyn, Chief Development Officer at RXi Pharmaceuticals Corp (RXII), bought 3,500 shares at $0.62 ($2K) on 2017-06-23, disclosed to the SEC on 2017-06-26.
Open-market purchase of $2k RXII by Chief Development Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| PHIO | BUY | 2021-03-03 | $8K | — | Filing → |
| PHIO | BUY | 2020-08-19 | $5K | — | Filing → |